Tesio, Cerela D.

HRN: 24-37-88  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/11/2024
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
01/11/2024
01/17/2024
IVT
500mg
Q8
E. Histolytica Infection
Waiting Final Action 
01/12/2024
MEBENDAZOLE 500MG (TAB)
01/12/2024
01/18/2024
PO
500 Mg
Q8H
E. Histolytica Infection
Waiting Final Action 
01/15/2024
METRONIDAZOLE 500MG (TAB)
01/13/2024
01/18/2024
PO
500mg
TID
Amoebiasis
Waiting Final Action 
01/15/2024
MUPIROCIN 2%, 15G (TUBE)
01/15/2024
01/20/2024
TOPICAL
Apply Thinly
BID
Skin Infection
Waiting Final Action 
01/15/2024
CEFTRIAXONE 1G (VIAL)
01/15/2024
01/21/2024
IV
2gm
OD
T/C Complicated UTI
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: